CTLA-4 Expression and Its Clinical Significance in Breast Cancer

IF 2.9 4区 医学 Q3 IMMUNOLOGY
Rodrigo Kern, Carolina Panis
{"title":"CTLA-4 Expression and Its Clinical Significance in Breast Cancer","authors":"Rodrigo Kern,&nbsp;Carolina Panis","doi":"10.1007/s00005-021-00618-5","DOIUrl":null,"url":null,"abstract":"<div><p>Breast cancer is the leading cause of women’s death among all cancers. The main reason associated with this is the development of metastasis and therapy-resistant breast carcinoma (BC), which pose the main challenge of oncology nowadays. Evidence suggest that these tumors seem to have inhibitory mechanisms that may favor their progression and surveillance. Cancer cells can evade antitumor T cell responses by expressing some immune inhibitory molecules such as the cytotoxic T-lymphocyte antigen-4 (CTLA-4), whose clinical meaning has emerged in the last few years and is poorly understood in the BC context. This systematic literature review aims at identifying studies on CTLA-4 expression in BC, and address what is known about its clinical meaning. A literature search was performed in PubMed and LILACS databases, using the MESH terms “breast cancer”; “CTLA-4 Antigen/antagonists and inhibitors”; and “Lymphocytes, Tumor-Infiltrating/immunology”, published in the last 10 years. In total, 12 studies were included in this review. Systematic review used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Despite the small number of eligible studies, the literature reports some associations between CTLA-4 expression in the tumor microenvironment and worse BC outcomes, regardless of its molecular subtype<b>.</b> CTLA-4 expression in BC is a putative marker of clinical significance and a rationale therapeutic target in the emerging field of immunotherapy.</p></div>","PeriodicalId":8389,"journal":{"name":"Archivum Immunologiae et Therapiae Experimentalis","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2021-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00005-021-00618-5","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivum Immunologiae et Therapiae Experimentalis","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00005-021-00618-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 17

Abstract

Breast cancer is the leading cause of women’s death among all cancers. The main reason associated with this is the development of metastasis and therapy-resistant breast carcinoma (BC), which pose the main challenge of oncology nowadays. Evidence suggest that these tumors seem to have inhibitory mechanisms that may favor their progression and surveillance. Cancer cells can evade antitumor T cell responses by expressing some immune inhibitory molecules such as the cytotoxic T-lymphocyte antigen-4 (CTLA-4), whose clinical meaning has emerged in the last few years and is poorly understood in the BC context. This systematic literature review aims at identifying studies on CTLA-4 expression in BC, and address what is known about its clinical meaning. A literature search was performed in PubMed and LILACS databases, using the MESH terms “breast cancer”; “CTLA-4 Antigen/antagonists and inhibitors”; and “Lymphocytes, Tumor-Infiltrating/immunology”, published in the last 10 years. In total, 12 studies were included in this review. Systematic review used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Despite the small number of eligible studies, the literature reports some associations between CTLA-4 expression in the tumor microenvironment and worse BC outcomes, regardless of its molecular subtype. CTLA-4 expression in BC is a putative marker of clinical significance and a rationale therapeutic target in the emerging field of immunotherapy.

CTLA-4在乳腺癌中的表达及临床意义
癌症是所有癌症中女性死亡的主要原因。与此相关的主要原因是转移和耐药乳腺癌(BC)的发展,这是当今肿瘤学面临的主要挑战。有证据表明,这些肿瘤似乎具有抑制机制,可能有利于其进展和监测。癌症细胞可以通过表达一些免疫抑制分子来逃避抗肿瘤T细胞反应,如细胞毒性T淋巴细胞抗原-4(CTLA-4),其临床意义在过去几年中已经出现,在BC背景下尚不清楚。这篇系统的文献综述旨在确定CTLA-4在BC中表达的研究,并阐述其临床意义。在PubMed和LILACS数据库中使用MESH术语“乳腺癌症”进行文献检索;“CTLA-4抗原/拮抗剂和抑制剂”;以及最近10年发表的“淋巴细胞,肿瘤浸润/免疫学”。本综述共纳入12项研究。系统评价使用了系统评价和荟萃分析的首选报告项目。尽管有少量符合条件的研究,但文献报道了CTLA-4在肿瘤微环境中的表达与较差的BC结果之间的一些关联,无论其分子亚型如何。CTLA-4在BC中的表达是一种公认的具有临床意义的标志物,也是新兴免疫治疗领域的基本治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
0.00%
发文量
26
审稿时长
>12 weeks
期刊介绍: Archivum Immunologiae et Therapiae Experimentalis (AITE), founded in 1953 by Ludwik Hirszfeld, is a bimonthly, multidisciplinary journal. It publishes reviews and full original papers dealing with immunology, experimental therapy, immunogenetics, transplantation, microbiology, immunochemistry and ethics in science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信